Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Candesartan Plus 32 mg/25 mg Tablet (DIN 02420740) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 1, 2021.** The following grouping was removed from the Critical Supply Product List **January 28, 2021.**

CANDESARTAN CILEXETIL / HYDROCHLOROTHIAZIDE

32 MG / 25 MG TABLET

00002421054	**AURO-CANDESARTAN-HCT**	AUR	$ 0.3008
00002473267	**JAMP CANDESARTAN-HCT**	JPC	$ 0.3008
00002420740	**SANDOZ CANDESARTAN PLUS**	SDZ	$ 0.3008
00002332957	ATACAND PLUS	AZC	$ 1.3077

Alberta Blue Cross has been advised by Actavis Pharma Company, UpJohn Canada ULC and Generic Medical Partners Inc. that the shortages for Act Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02436256), GD-Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02373068), and Med-Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02454505), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 4, 2021.** The following grouping was removed from the Critical Supply Product List **February 2, 2021.**

LATANOPROST/ TIMOLOL MALEATE

0.005% / 0.5 % OPHTHALMIC SOLUTION

00002436256	**ACT LATANOPROST/TIMOLOL**	APH	$ 4.4268
00002373068	**GD-LATANOPROST/TIMOLOL**	UJC	$ 4.4268
00002453770	**JAMP-LATANOPROST/TIMOLOL**	JPC	$ 4.4268
00002489368	**LATANOPROST AND TIMOLOL**	TGT	$ 4.4268
00002454505	**MED-LATANOPROST-TIMOLOL**	GMP	$ 4.4268
00002246619	XALACOM	UJC	$ 13.7543

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Dabigatran 150 mg Capsule (DIN 02468913) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 1, 2021.** The following grouping was removed from the Critical Supply Product List **January 29, 2021.**

DABIGATRAN ETEXILATE

    150 MG CAPSULE

00002468913	**APO-DABIGATRAN**	**APX**	**$ 1.2540**
00002358808	PRADAXA	BOE	$ 1.7121

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Jamp-Quinine 300 mg Capsule (DIN 02445204) manufactured by Jamp Pharma Corporation and Teva-Quinine 300 mg Capsule (DIN 00021016) manufactured by Teva Canada Limited, Quinine-Odan 300 mg Capsule (DIN 00695459) will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL).* The following grouping was added to the Critical Supply Product List **February 3, 2021.**

As of **February 3, 2021,** all claims for Quinine-Odan 300 mg Capsule (DIN 00695459) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **https://www.ab.bluecross.ca/providers/pharmacy-home.php**.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit **ab.bluecross.ca/providers/pharmacy-home.php**